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The mucus layer covering all mucosal surfaces in our body is the first barrier encountered by 
drugs before their potential absorption through epithelial tissues, and could thus affect the 
drugs’ permeability and their effectiveness. Therefore, it is of key importance to have in vitro 
permeability models that can mimic this specific environment. For this purpose, the novel 
mucus phospholipid vesicle-based permeation assay (mucus-PVPA) has been developed and 
used for permeability screening of drugs and formulations. The model proved to be stable 
under the chosen conditions and demonstrated the ability to discriminate between compounds 
with different chemical structures and properties. Overall, a decrease in drug permeability was 
found in the presence of mucus on top of the PVPA barriers, as expected. Moreover, 
mucoadhesive (chitosan-coated) and mucopenetrating (PEGylated) liposomes were 
investigated in the newly developed model. The mucus-PVPA was able to distinguish 
between the different liposomal formulations, confirming the penetration potential of the 
tested formulations and the related drug permeability. The mucus-PVPA model appears to be 
a promising in vitro tool able to mimic the environment of mucosal tissues, and could 
therefore be used for further drug permeability screening and formulation development. 
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The mucus layer covering mucosal epithelia is the first barrier encountered by many drugs 
and formulations when entering the body. This layer could thus potentially limit the 
effectiveness of most drug delivery systems (Groo and Lagarce, 2014). Mucus is found on 
many epithelial surfaces such as the gastrointestinal tract (GI), the respiratory tract, the eye 
and the female genital tract; its composition, structure and thickness differ according to the 
different locations in the body (Friedl et al., 2013; Leal et al., 2017; Sigurdsson et al., 2013). 
The main components of mucus are water, glycoproteins (i.e. mucins), free proteins, salts and 
lipids (Groo and Lagarce, 2014). An important role is played by mucins, negatively charged 
glycoproteins (polypeptide backbone with oligosaccharide side chains), which are secreted by 
mucosal glands and goblet cells (Leal et al., 2017; Sigurdsson et al., 2013). The structure of 
the mucin gel can hinder the diffusion of drugs (Boegh and Nielsen, 2015) by two main 
mechanisms, namely the interaction and size filtering (Olmsted et al., 2001).  
Transmucosal drug delivery gained increasing attention in the past two decades. Various 
strategies have been proposed to improve the mucosal permeability of drugs, including 
mucoadhesive and mucopenetrating systems, such as liposomes (Leal et al., 2017). Therefore, 
to properly tackle the screening of new drugs and optimization of novel mucosal 
formulations, it is of key importance to exploit in vitro tools comprising mucus to better 
understand its impact on drug permeation and absorption and to better predict the fate of a 
drug in vivo. Many models have been developed to study the effect of the sole mucus layer on 
drug permeability, without the presence of an artificial membrane. Some of them comprise the 
use of native mucus and some others exploit the use of commercially available mucins in 
different types of media (Khanvilkar et al., 2001; Legen and Kristl, 2001; Matthes et al., 
1992). However, it has to be noted that the removal of mucus from its physiological 
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environment can modify its characteristics (e.g. gel-forming properties) (Kocevar-Nared et 
al., 1997). Therefore, it becomes challenging to produce a model able to mimic physiological 
mucus, and the differences between native and reconstituted mucus can lead to variances in 
the resulting drug permeability. On the other hand, to date, several in vitro cell-based (Caco-2 
model, Artusson et al., 2001) and artificial models (PVPA model, Flaten et al., 2006b; 
PAMPA model, Kansy et al., 1998; PermeapadTM, di Cagno et al., 2015; AMI-system, Berben 
et al., 2017) have been developed for the screening of new drugs and formulations. Some of 
those models also include the mucus layer, such as mucus-producing cell systems (i.e. 
Caco2/HT29-MTX co-culture) and cell-based mucosal models with artificial mucus (Boegh et 
al., 2014; Lechanteur et al., 2017). Unfortunately, the robustness and reproducibility of these 
mucus-including models are not yet well defined. Therefore, the lack of a reliable artificial in 
vitro model comprising mucus remains a considerable limitation for permeability studies 
targeting the mucosal administration route. 
Among the non-cell-based models, the phospholipid vesicle-based permeation assay 
(PVPA) has been developed in our group and established in the past decade as a predictive 
and reliable artificial model for the screening of drugs and optimization of formulations 
(Flaten et al., 2006b; Flaten et al., 2011; Kanzer et al., 2010; Naderkhani et al., 2014a,b). So 
far, this model has not taken into account the crucial influence of mucus on the permeation of 
drugs. Therefore, in this study, the effect of mucus on drug permeability was assessed and the 
novel mucus-PVPA developed and validated. The permeability of five model drugs (atenolol, 
ibuprofen, indomethacin, metronidazole and naproxen) was investigated. The drugs were 
chosen to cover a range of relevant physicochemical properties to challenge the mucus-
PVPA’s ability to distinguish between drugs with different physicochemical characteristics. 
Moreover, since nanoparticulate formulations have demonstrated great efficacy in in vitro and 
in vivo experiments (Chen et al., 2013; Netsomboom and Bernkop-Schnürch, 2016), a focus 
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was put on the permeation of three selected drugs (indomethacin, metronidazole and 
naproxen) from mucoadhesive (chitosan-coated) and mucopenetrating (PEGylated) liposomal 
formulations, to better understand the influence of the mucus layer on the diffusion of the 
nanocarriers and permeability of the drugs contained in such delivery systems. 
 




Lipoid egg phospholipids E80 (80% phosphatidylcholine), Lipoid soybean lecithin S100 
(>94% phosphatidylcholine) and Lipoid PE 18:0/18:0 (PEG 2000) were obtained from Lipoid 
GmbH (Ludwigshafen, Germany). Acetic acid (≥99.8%), ammonium molybdate, atenolol, 
calcein, chitosan (low molecular weight, Brookfield viscosity 20,000 cps, degree of 
deacetylation 92%), chloroform, ethanol (96%, v/v), Fiske-Subbarow reducer, hydrochloric 
acid, ibuprofen, indomethacin, methanol CHROMASOLV®, metronidazole, mucin from 
porcine stomach type III (bound sialic acid 0.5-1.5%, partially purified), naproxen, 
phosphorus standard solution, potassium phosphate monobasic, sodium chloride, sodium 
hydroxide and sodium phosphate dibasic dodecahydrate were products of Sigma-Aldrich, 
Chemie GmbH (Steinheim, Germany). Hydrogen peroxide 30% and titriplex® III were 
purchased from Merck KGaA (Darmstadt, Germany). Acetonitrile for HPLC (gradient grade) 
was obtained from VWR chemicals (Fontenay-sous-Bois, France) and sulfuric acid was 
purchased from May&Baker LTD (Dagenham, England). All chemicals employed were of 
analytical grade. 
Plates and Transwell filter inserts (d = 6.5 mm) were products of Corning Inc. (Corning, New 
York). The nitrocellulose membrane filters (0.65 µm DAWP) were obtained from Millipore 
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(Billerica, Massachusetts) and the Nucleopore track-etch membrane filters (0.4 and 0.8 µm 
pore size) were purchased from Whatman (part of GE Healthcare, Oslo, Norway). 
 
2.2. PVPA barriers preparation 
 
The PVPA barriers were prepared by depositing egg-phospholipid liposomes on top of 
cellulose ester filters by centrifugation followed by a freeze-thaw cycle according to a method 
previously described (Naderkhani et al., 2014a). 
 
2.3. Mucus barrier 
 
Different concentrations of mucin (10, 20 and 40 mg/mL) were used as a model for the 
mucus layer. These suspensions were obtained by the hydration of mucin from porcine 
stomach type III with phosphate buffer saline (PBS) pH 7.40. The viscosity of the mucus was 
measured at room temperature on HAAKE ViskoTester 7 plus (Thermo, Hafrsfjord, Norway) 
using spindle TL5. In the in vitro permeability studies, the mucin suspension was directly 
pipetted on top of the PVPA barriers before the addition of the drugs or formulation to be 
tested. The drug solutions/formulations were carefully added on top of the mucus layer in the 
donor compartment in order to prevent mixing of the two layers. The division of the two 
layers was visibly distinct. 
 
2.4. In vitro permeability study using the mucus-PVPA 
 
The permeability of different drugs/marker (calcein, CAL; atenolol, ATN; ibuprofen, 
IBP; indomethacin, IND; naproxen, NPR; metronidazole, MTR; Table 1) was investigated at 
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room temperature (23-25 °C) in the presence and absence of mucus following the procedure 
previously described (Naderkhani et al., 2014a). In the experiments performed in the presence 
of mucus, 50 µL of mucin 10 mg/mL were added, if not stated otherwise, before the careful 
addition of drug/marker. To maintain sink conditions, the inserts were moved to a new 
acceptor compartment at certain time intervals for 5 hours. After ended experiment, the 
electrical resistance was measured to confirm the integrity of the barriers and the samples 
collected as previouslu described (Flaten et al., 2006 a,b; Naderkhani et al., 2014 a,b)The 
fluorescent marker calcein was used to monitor the barriers’ integrity during the study (Flaten 
et al., 2006b) and was quantified spectrofluorometrically on POLARstar Galaxy fluorometer 
(Fluostar, BMG Labtechnologies, Offenburg, Germany) at excitation and emission 
wavelengths of 485 and 520 nm, respectively. The quantification of indomethacin was carried 
out by HPLC using a Waters X-selectTM CSH TM C18 (2.5 µm, 3.0x75 mm) XP column 
preceded by a Waters X-selectTM CSH TM C18 (3.5 µm, 3.0x20 mm) guard cartridge on a 
Waters e2795 Separation Module connected to a Waters 2489 UV/Visible Detector (Waters, 
Milford, Massachusetts, USA) at a wavelength of 254 nm. The mobile phase consisted of 
acetonitrile and MilliQ water (60:40, v/v) with 0.1% glacial acetic acid and the flow rate was 
set at 0.5 mL/min (retention time 2.8 minutes). Atenolol, ibuprofen, metronidazole and 
naproxen were quantified spectrophotometrically on SpectraMax 190 Microplate reader 
(Molecular Devices Corporation, California, USA) at wavelengths of 274, 220, 320 and 270 
nm, respectively. 
For each compound the experiment was performed at least in triplicates (6 inserts for 
each parallel) and the apparent permeability coefficient (Papp) was calculated with the 















where 𝑑𝑄/d𝑡 is the slope at the steady-state conditions (nmol/s), A represents the surface area 
of the PVPA barriers (cm2) and Cd is the concentration of the compound in the donor 
compartment (nmol/mL). 
 As earlier described by our group (Flaten et al., 2006a, b), the concentrations of the 
drugs investigated in the study were chosen in order to reach a concentration in the acceptor 




2.4.1. The effect of temperature, mucus volume and mucin concentration on the 
permeability of drugs  
 
The permeability of different drugs/marker (Table 1) was measured in the absence and 
presence of mucus at 37 °C and compared to the one obtained at room temperature (23-25 °C) 
to evaluate possible changes in permeability due to elevated temperature. Different 
concentrations of mucin (10, 20 and 40 mg/mL) were tested to estimate their effect on the 
permeability of the tested compounds. Moreover, different volumes of mucus (mucin 10 
mg/mL; mucus volume range: 20-50 µL) were deposited on top of the PVPA barriers, and the 
permeability of naproxen was measured to assess if the different mucus’ volumes would have 
any effect on the drug’s permeability. 
 
2.5. PVPA barriers – mucus interaction 
 




In order to determine any changes in the barriers’ integrity caused by the addition of 
mucus on top of the PVPA barriers, the amount of phospholipids released after the addition of 
the mucus layer was measured by the modified phosphorus assay (Bartlett, 1959) as 
previously described by us (Naderkhani et al., 2015).  
 
2.5.2.  In vitro mucus binding test 
 
The binding potential of the egg-phospholipid liposomes to mucus was evaluated to 
determine its interaction with the PVPA barriers. The study was conducted as previously 
described (Jøraholmen et al., 2017). The experiment was carried out in triplicate and the 
binding efficiency of mucus to the liposomes was calculated according to Jøraholmen and 
colleagues (2017). 
 
2.6. Preparation of liposomal formulations 
 
Three different types of liposomal formulations containing either indomethacin (IND), 
metronidazole (MTR) or naproxen (NPR) were prepared to study the effect of the formulation 
on drug permeability.  
Plain liposomes were obtained using the film hydration technique, according to the 
method described by Berginc and colleagues (Berginc et al., 2014). The liposome dispersion 
was sonicated for 1 minute using a Sonics high intensity ultrasonic processor (Sonics & 
Materials Inc., Newtown, Connecticut) (amplitude setting of 500 W/20 kHz processor 40%) 
to produce a smaller and more homogeneous size distribution. The sonicated liposome 
dispersion was stored in the refrigerator for at least 2 hours prior to further use. 
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Chitosan-coated liposomes were prepared from plain liposomes in the absence of 
unentrapped drug as previously described (Jøraholmen et al., 2014; Naderkhani et al., 2014a). 
After storage in refrigerator (4-8 °C) overnight, the pH was measured and adjusted to 7.40. 
PEGylated liposomes were prepared using Lipoid S100 (200 mg), PEG 2000 (36.3 mg) 
and the drug (IND, MTR or NPR; 20 mg), following the method described by Jøraholmen and 
colleagues (Jøraholmen et al., 2017). 
 
2.7. Characterization of liposomal formulations 
 
2.7.1.  Entrapment efficiency and recovery  
 
The encapsulated drug (IND, MTR or NPR) in the different liposomal formulations was 
separated from the unentrapped drug by dialysis using a dialysis tubing with a MWCO 12-
14,000 Da (Medicell International Ltd., London, UK). The liposomal dispersions (4.2 mL) 
were dialyzed against a medium (PBS, pH 7.40) for 6 hours at room temperature. The volume 
of PBS was adjusted to assure the solubility of the drugs. Aliquots of the dialyzed liposomes 
were dissolved in MeOH to free the drug contained in the liposomes and compared with the 
amount of drug in the medium (unentrapped drug) to calculate the entrapment efficiency for 
the specific drug. Drugs were quantified as previously described in section 2.4. 
 
2.7.2. Size analysis and zeta potential measurements 
 
The diameter of the dialyzed liposomes containing different drugs was determined using 
a Malvern Zetasizer Nano ZS (Malvern, Oxford, UK). Two samples for each batch of 
liposomes were analysed and the diameters calculated from the mean of three measurements 
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for each sample. The liposome dispersions were diluted 1:50 (v/v) in PBS pH 7.40 for plain 
and PEGylated liposomes, and PBS pH 7.40 and acetic acid 0.1% (1:1 v/v) for the chitosan-
coated ones, in order to dilute the formulations in their own preparation media. The 
polydispersity index (PI) of each batch was measured to assess the population’s homogeneity. 
All liposomal formulations (plain, chitosan-coated and PEGylated) were diluted 1:10 
(v/v) in freshly filtered water (0.2 µm filters) to determine the zeta potential using a Malvern 
Zetasizer Nano ZS (Malvern, Oxford, UK). The disposable folded capillary cells (DTS1070) 
were cleaned before the loading of the sample using ethanol and filtered water. Two samples 
for each batch of formulations were measured in three parallels at room temperature. 
 
2.8. Statistical analysis 
 
Statistical analysis was done using GraphPad Prism 7.0 software. Student’s t-test was used to 
detect significant differences between two sets of data (p < 0.05). Comparisons between three 
or more groups were performed using one-way ANOVA and significance (p < 0.05) was 
found out using the Bonferroni multiple comparison post hoc test. 
 
3. Results and discussion 
 
Mucosal tissues, found at various locations in the body, can provide access to both local 
and systemic drug administration, and are an interesting barrier considering transmucosal 
delivery (Leal et al., 2017). Moreover, mucosal administration is seen as one of the most 
convenient, easy and cost-effective routes (Lechanteur et al., 2017). However, the mucus 
layer covering all mucosal tissues represents a barrier that drugs must overcome to reach 
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deeper epithelia or become absorbed. Therefore, it is of key importance to develop reliable in 
vitro tools able to evaluate the effect of mucus on drug permeability. 
 
3.1. The effect of mucus on the PVPA barriers 
 
The mucus-PVPA model is expected to provide fast and reliable means to 
predict/optimize the permeation of drugs once in contact with mucosal surfaces. Unpurified 
mucin type III from porcine stomach was employed, since this type of mucin has already been 
exploited in several other studies (Berben et al., 2017; Griffiths et al., 2010; Jøraholmen et al., 
2017); the molecular weight and structure of pig mucins resemble human mucins (Groo and 
Lagarce, 2014). Moreover, its preparation avoids the degradation that occurs with purified 
mucin type II; the degradation often leads to a different mesh structure and related different 
rheological properties compared to native mucus (Groo and Lagarce, 2014). To assess 
whether the mucus-PVPA can provide reliable evidences on drug permeability, the integrity 
and functionality of the barriers were investigated. The permeability of the hydrophilic marker 
calcein in the presence of mucus served as a model. Moreover, the effect of different mucus 
layer thicknesses on the permeability of a model drug as well as characterization of the 
interaction between mucus and the PVPA barriers were evaluated. 
 
3.1.1. Permeability of a highly hydrophilic marker 
 
The permeability of the hydrophilic marker calcein was investigated in the presence of 
different mucin concentrations to study their effect on permeability. This fluorescent marker 
provides information on potential aqueous pathways in the PVPA barrier (Flaten et al., 
2006b). Fig. 1 shows that there was no significant change in calcein’s Papp in the absence or 
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presence of different concentrations of mucin. Considering mucus’ overall hydrophilicity and 
negative charge, more hydrophilic compounds have exhibited lower affinity for mucus 
compared to hydrophobic ones (Boegh et al., 2014). Boegh et al. (2014) have compared the 
permeability of a hydrophilic drug (mannitol) with a hydrophobic one (testosterone) in the 
presence and absence of biosimilar mucus on top of Caco-2 cell monolayers. The authors 
have found that the greatest reduction in permeability in the presence of mucus was obtained 
for the hydrophobic drug compared to the hydrophilic one. In our case, considering calcein 
chemical properties (Table 1), it was not expected that its permeability should be affected to a 
great extent by the presence of the mucus layer. Therefore, the lack of changes in permeability 
in the presence of mucus indicates that calcein is free to diffuse through the mucus layer and 
to permeate through the PVPA barriers without any considerable interaction with this 
hydrophilic layer. Moreover, as previously stated, no increase in calcein permeability suggests 
that the barriers are able to maintain their integrity in the presence of mucus. Furthermore, the 
electrical resistance remained constant in all of the tested conditions (Fig. 1), also indicating 
no significant changes in the barriers' integrity. These findings are of significant importance 
especially when compared to the already established cell-based in vitro models including the 
mucus layer such as the Caco-2/HT29-MTX (Hilgendorf et al., 2000). The major drawback of 
the Caco-2/HT29-MTX model is related to the decrease in transepithelial electrical resistance 
(TEER) produced by the introduction of the mucus-producing HT29-MTX goblet cells 
(Schimpel et al., 2014). In fact, the presence of these cells lead to a leakier Caco-2 cell 
monolayer, thus suggesting an uncertain relevance in comparison of the permeability between 
the presence and absence of mucus (Lechanteur et al., 2017). On the contrary, in our case, the 
addition of mucus on top of the barriers did not cause any change in electrical resistance, 






3.1.2. Characterization of the interaction between mucus and the PVPA barrier  
 
To assess possible disintegration events taking place in the barrier when exposed to 
mucus, the release of phospholipids from the PVPA barriers into the donor chamber in the 
presence of mucus (mucin 10 and 40 mg/mL) was quantified and compared to the release in 
the presence of PBS pH 7.40 on top of the barriers (control). Results (data not shown) 
indicated that no significant difference in phospholipid release was found in the presence and 
absence of mucus. This evidence is in agreement with previous reports on the robustness of 
the original PVPA barriers (Flaten et al., 2008) and confirms the maintenance of the barriers’ 
integrity and their low degree of interaction with mucus. 
To further test the potential interaction between the liposomes in the PVPA barriers and 
mucus, a mucin binding test was performed. The results obtained (data not shown) confirmed 
a lack in binding between the two components, especially evident for liposomes with bigger 
diameter size, comparable to the liposome size on top of the PVPA barrier. This evidence 
highlights, once again, the lack of changes produced in the PVPA barriers by the mucus layer. 
The lack of structural changes in the barriers was also suggested by studies performed 
using the confocal laser scanning microscopy (CLSM) (results in Supplementary). The PVPA 
barriers were investigated to visually examine if the mucus layer would interfere with the 
barrier’s integrity. The micrographs of the cross-sectioned PVPA barriers showed that no 
aqueous channels were present throughout the barriers, thus confirming the intact integrity of 
the barriers for all the tested conditions, and that calcein was mainly present in the donor side 
of the PVPA barrier. These findings are in agreement with previous reports from confocal 




3.1.3.  Viscosity, composition and structure of the mucus layer 
 
Since mucin is the major determinant in mucus rheology (Sigurdsson et al., 2013), the 
viscosity measurements were performed to study the effect of different mucin concentrations 
(Fig. 2). The tested suspensions exhibited a Newtonian character, with lower viscosity of 
mucin in concentration of 10 mg/mL compared to the mucin in higher concentrations. The 
increase in viscosity with increasing mucin concentrations correlates well with the gel-
forming effect of mucin (Grießinger et al., 2015; Dawson et al., 2004). Although the in vivo 
mucus layer has been reported to be of non-Newtonian character (viscoelastic with shear-
thinning properties), studies have reported that the hydrated mucin type III from porcine 
stomach exhibits a Newtonian behaviour (Mackie et al., 2017; Boegh and Nielsen, 2015). 
Moreover, a comparison between the viscosity of human saliva and porcine gastric mucin was 
proposed by and Park and colleagues (Park et al., 2007). Both human saliva and animal mucin 
suspensions exhibited similar viscosities with increasing shear rates. Furthermore, an increase 
in viscosity was found with increasing mucin concentrations, as also found in our analyses. 
As previously stated, the composition and concentration of mucin vary in the body 
depending on the location and function of the mucosal tissue. However, mucin accounts for 
generally not more than 5% of the mucus components (Griffiths et al., 2010). Even though the 
differences in viscosity have to be taken into account when developing a new model, they are 
only one of the factors affecting the diffusion of drugs through the mucus (Shaw et al., 2005). 
For these reasons, mucin in concentration of 10 mg/mL (viscosity 2.1 mPa*s) was used as a 






The mucus-simulating media used in this study was prepared using solely unpurified 
mucin from porcine stomach type III. Constituents such as lipids, proteins and DNA were not 
added to keep the mucus-simulating layer as simple as possible and to be a general model for 
mucus, since the content of the other components can vary according to the different site, 
different species and the specific physiopathological condition (Lieleg et al., 2010). Our aim 
was to investigate if the presence of sole mucin would affect the permeation of the drugs 
through the PVPA barriers, and we concluded that it did. However, as reported by Larhed and 
colleagues (Larhed et al., 1998), other components can significantly hinder the diffusion of 
drugs through the mucus layer. In particular, the authors found that lipids had a major role in 
reducing the diffusion of drugs in native pig intestinal mucus. Moreover, it has to be kept in 
mind that a model mucus system made only out of mucin cannot be considered entirely 
equivalent to natural mucus, most likely due to the changes in physico-chemical properties 
caused by the mucin isolation procedures (Kocevar-Nared et al., 1997). 
With regards to mucus structure, scanning electron microscopy images of mucin from 
porcine stomach type III have been obtained by Teubl and colleagues (Teubl et al., 2013). The 
authors suggested a structural similarity between mucin from porcine stomach and human 
salivary mucin fibres. The mucus mesh size was also determined for both samples (pore size 
up to 0.9 µm for porcine gastric and 0.8 µm for human mucin). These results can be compared 
to the ones by Bajka and colleagues (Bajka et al., 2015), who have investigated ex vivo 
porcine mucus and who have estimated the main pore diameter of the mucin sheets to be 
around 200 nm. The different results obtained in these two studies could be traced back to the 
different sample preparation methods and different sample origin (Huckaby and Lai, 2017). 
These considerations can give us an estimation on how the mucus layer on the PVPA barriers 
may look like compared to both human and animal mucus and on how particles/formulations 
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could diffuse through this layer, together with the pore size of the mucin mesh. However, it 
has to be taken into consideration the fact that the structure and composition of the mucus 
layer differs according to different animal species and different sites of the body (Huckaby 
and Lai, 2017) and that the mucus-PVPA model so far is aimed to be established as an 
artificial model for mucosal tissues in general. 
 
3.1.4. Permeability study: the effect of the mucus layer thicknesses 
 
To assess possible changes in drug permeability related to different mucus layer 
thicknesses on top of the PVPA barriers, the permeability of naproxen was measured in the 
presence of different volumes of mucus (mucin 10 mg/mL). The thickness of the mucus layer 
has been reported to be around 600 µm in the human stomach and 50-450 µm in the intestine 
and colon (Fig. 3, black arrow), although this might vary depending on fasted and fed state 
(Boegh and Nielsen, 2015; Shaw et al., 2005), and the thickness in the respiratory tract, in the 
female reproductive tract and the ocular mucus layer varies according to the specific site 
(Huckaby and Lai, 2017; Khanvilkar et al., 2001). For the naproxen permeability experiment, 
20, 22, 25 and 50 µL of mucus, respectively, were added on top of the barriers and the 
thickness of the layer (Fig. 3, shaded area) was calculated from the surface area of the filter 
support. Results showed that there was a significant difference in naproxen's Papp when tested 
in the presence or absence of mucus (addressed in section 3.2), but there was no significant 
variation between the different mucus volumes/thicknesses. Therefore, even though the 
calculated mucus layer thickness for 50 µL of mucin suspension exceeded the physiological 
range, it was considered the best volume to use. This volume assured that the whole surface 







3.2. Permeability of drugs in solution using the mucus-PVPA 
 
Four different model drugs (naproxen, indomethacin, ibuprofen and atenolol) were used 
both to evaluate whether the additional mucus layer would affect their permeability and to 
further highlight whether different mucin concentrations (10, 20 and 40 mg/mL) would have 
an effect on drug permeability. The drugs were chosen to cover a range of relevant 
physicochemical properties (Table 1) 
Fig. 4 shows that for all drugs there was a significant decrease (p < 0.05) in permeation 
with the addition of the mucus layer. This behaviour was to be expected especially for the 
more lipophilic drugs (naproxen, indomethacin and ibuprofen), whereas a decrease in 
permeability was not expected for the more hydrophilic atenolol. However, Boegh and 
colleagues (2014) have previously reported a significant decrease in permeability of the 
hydrophilic drug mannitol in the presence of a biosimilar mucus layer on Caco-2 cell 
monolayer, highlighting the fact that mucus can represent a barrier to both hydrophilic and 
lipophilic drugs. In fact, it has to be taken into account that there are multiple mechanisms 
taking place during diffusion of drugs through the mucus layer before the permeation process, 
and that especially mucins’ properties can influence mucus’ barrier characteristics. Mucins 
are formed by a polypeptide backbone to which oligosaccharide side chains are attached, 
resembling the structure of a bottle-brush. These two different regions provide mucins with 
both a hydrophobic (protein backbone) and hydrophilic (glycosylated regions) nature, which 
can affect the diffusion of various types of drugs and formulations (Peppas and Huang, 2004). 
Moreover, in Olmsted et al. (2001) it is suggested that there are two major mechanisms 
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hindering compounds from diffusing through this layer: i) the interaction filtering, dependant 
on the electrostatic, hydrophobic forces, hydrogen bonds and specific binding interactions, 
and ii) the size filtering properties of the mucin mesh. However, the overall hydrophilicity of 
the mucin gel mostly affects lipophilic compounds, whereas hydrophilic ones tend to be freer 
to penetrate through (Boegh and Nielsen, 2015). In fact, it has been demonstrated how 
lipophilic drugs are able to interact with the non-glycosylated regions of the mucin 
macromolecule (naked protein region), which provide an area for a hydrophobic interaction 
with the drug. Therefore, the interaction between a lipophilic drug and mucin’s hydrophobic 
region can slow down its diffusion through the mucus layer (Khanvilkar et al. 2001). On the 
other hand, for the hydrophilic compounds, their ionization can be the driving force of the 
diffusion through the mucus (Shaw et al., 2005). 
In conclusion, the use of differently viscous mucus layers (mucin concentration of 10, 20 
or 40 mg/mL) did not lead to differences in permeability of all of the tested drugs (Fig. 4), 
even though an increase in viscosity could suggest a slowed-down diffusion through mucus 
and a lower permeability through the barrier. Therefore, since no direct correlation was found 
between the concentration of mucin in the mucus layer and the drugs’ permeability, mucin 10 
mg/mL was chosen as the preferred suspension since it was the easiest to handle from a 




Fig. 5 shows the permeabilities of different compounds in the presence and absence of 
mucus (no mucin or 10 mg/mL mucin suspension, respectively) at room temperature (23-25 
°C) and at the physiological temperature (37 °C). The permeability of the fluorescent marker 
calcein was measured at both temperatures to assure that the barriers would maintain their 
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integrity in both conditions. In all experiments, the electrical resistance was found to be in the 
range reported for the barriers with maintained integrity (Flaten et al., 2008). The different 
Papps of the tested drugs confirmed the ability of the barriers to discriminate between 
compounds with different chemical structures and properties (Table 1) both for the original 
PVPA barriers and for the novel mucus-PVPA ones. Although some of the chosen drugs had 
similar chemical properties, the resulting permeability values were found to be compound-
dependent, confirming that multiple forces are responsible for the diffusion and permeation of 
drugs, and that an in vitro screening model should be able to highlight different 
characteristics, especially in relation to mucus-drug interaction. The permeability of all the 
tested drugs further increased at 37 °C, most probably due to a more fluid lipid layer of the 
barriers and potentially a lower viscosity connected to the higher temperature. In general, the 
addition of mucus on top of the PVPA barriers led to a significant decrease in permeability at 
both temperatures as earlier discussed and as expected due to the intrinsic characteristic of 




However, if all drugs/marker would have behaved identically in presence of the mucus 
layer compared to its absence, one could conclude that the rate-limiting factor could be the 
different diffusive pathway between the original PVPA barriers and the mucus-PVPA model. 
Nevertheless, what we have found in our study was that the permeabilities were linked to the 
chemical structure and physiochemical properties of the drug/marker and to the possible 
interactions with the mucus layer. For this reason, we believe that the interaction with this 
layer, rather than the longer diffusive pathway, is the important factor influencing the 
permeability of the compounds analysed in this study. 
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Permeability experiments were also carried out on filters covered with mucus only 
(without the phospholipid vesicle barrier), in order to assess the contribution of the sole 
mucus layer on the permeability of the drugs. However, it was found that the filters were not 
able to hold the mucus in the donor compartment (58.82 ± 2.57 % of the total amount of 
mucus that was placed on top of the filters was found in the acceptor medium after 5 hours). 
Due to this, it was not possible to assess the contribution of the mucus layer alone and 
compare it to the PVPA or mucus-PVPA model.  
A correlation between permeability coefficients of model drugs obtained with the PVPA 
model, other well known models (such as Caco-2 and PAMPA) and the fraction absorbed in 
humans after oral administration was already assessed in previous studies (Flaten et al., 
2006b; Naderkhani et al., 2014b). The novel mucus-PVPA model was still able to correctly 
classify the different model drugs in the same way the original model did (poorly, moderately 
and excellently absorbed drugs), even though Papp values significantly changed with the 
addition of mucus compared to its absence. 
 
3.3. Permeability of liposome-associated drugs using the mucus-PVPA  
 
Concerning mucosal administration, nanoparticulate mucoadhesive and mucopenetrating 
formulations have demonstrated great efficacy in multiple in vitro and in vivo studies, for both 
local and systemic drug delivery, confirming their innovative contribution to the 
pharmaceutical development (Netsomboom and Bernkop-Schnürch, 2016). In particular, 
liposomes have been established as promising carriers to improve the absorption of poorly 
absorbed drugs and several liposomal products are already on the market (Allen and Cullis, 
2013). Mucoadhesive formulations (e.g. chitosan-coated liposomes) can actively interact with 
the mucus layer, extending the resident time in the application site and increasing the local 
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concentration of the drug contained in the delivery systems (Boegh and Nielsen, 2015). On 
the other hand, mucopenetrating formulations (e.g. PEGylated liposomes) are able to avoid 
the interaction with the mucus layer, accessing the underlying epithelia in a more effective 
manner (das Neves et al., 2011; Lai et al., 2011; Mahmood et al., 2017). 
The optimal formulation should be able to assure a high drug concentration at the 
administration site and consequently a concentration gradient, allowing a passive diffusion 
across the mucus layer. In this study, plain, chitosan-coated  and PEGylated liposomes have 
been chosen as model drug delivery systems to get their diffusive properties be tested on the 
novel mucus-PVPA model. We have already tested mucoadhesive and plain liposomes on the 
original PVPA (Naderkhani et al., 2014a). However, we realized the importance of the 
presence of mucus to optimize the estimation of the penetration potential of nanosystems. 
 
3.3.1. The effect of the delivery system on drug permeability in the mucus-PVPA 
 
The degree of interaction with mucus largely depends on the size and surface properties 
of the delivery system. It has been reported that by increasing the particle size of a delivery 
system from 124 to 560 nm the amount transported in time through the mucus layer 
significantly decreases due to a stronger steric impediment (Sanders et al., 2000). Moreover, 
Takeuchi et al. (2001) have found that 100 nm liposomes are able to diffuse through the 
mucus layer to a higher extent compared to bigger ones. However, the surface properties of 
the delivery system could also dictate its interaction with mucus, making the size the 
secondary diffusion driving force. It has been demonstrated that nanosystems bearing a 
positive charge are able to actively interact with the negatively charged mucus layer, 
producing a mucoadhesion effect (e.g. chitosan-coated particles) (Mackie et al., 2017), 
whereas slightly negatively charged and neutral systems would favour a higher diffusion 
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ability thanks to their lack of interaction with such layer (e.g. PEGylated particles) (Griffiths 
et al., 2010; Jøraholmen et al., 2017; Lieleg et al., 2010). However, the particles that are 
strongly attracted to mucus would be completely immobilized, whereas excessively 
negatively charged particles would be repulsed and unable to diffuse through such a layer 
(Groo and Lagarce, 2014; Lieleg et al., 2010). Lieleg and colleagues have confirmed that 
particles’ mobility through the mucus layer is particularly influenced by their surface charge. 
They suggested that charged particles can interact via electrostatic interaction with mucin, 
slowing down their diffusion through the mucus layer (Lieleg et al., 2010). The authors have 
compared the diffusion through mucus of differently functionalised particles at different pHs, 
and found out that at neutral pH the diffusion of charged particles was not majorly hindered 
compared to that of neutral particles, whereas at pH 3 there was a significant difference in the 
diffusion of neutral and charged formulations. Moreover, according to the results from Lieleg 
et al., the zeta potential of the PEGyalted particles changed with the different pH conditions 
(neutral surface potential at pH 3 and negative at pH 7, Lieleg et al., 2010). 
In our study, plain, chitosan-coated and PEGylated liposomes were prepared 
incorporating three different drugs, respectively (Table 2). The size of the liposomes ranged 
between 100 and 200 nm and the liposome dispersions exhibited a bimodal size distribution 
with varying polydispersity indexes (PI), depending on the formulation. The zeta potential 
varied between the different formulations and was dependant on the incorporated drug. 
However, the coating process led to an increase in zeta potential for the chitosan-coated 
formulations, as expected (Berginc et al., 2014). It has to be highlighted that the PEGylated 
formulations exhibited a negative zeta potential for all the drugs incorporated and this 
characteristic could be of a key importance regarding the mucus-penetrating properties (Groo 
and Lagarce, 2014). The fact that negatively charged nanocarriers have the characteristics of 
being mucopenetrating is also supported by the results from Chen et al. (Chen et al., 2013). 
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Moreover, the surface potential of PEGylated liposomes obtained by Jøraholmen and 
colleagues, confirms the fact that PEG grafting can produce negatively charged liposomes 
(Jøraholmen et al., 2017). The entrapment of the three model drugs varied depending on their 
chemical properties All formulations were prepared according to the methods reported by 
Jøraholmen and colleagues (Jøraholmen et al., 2014; Jøraholmen et al., 2015; Jøraholmen et 
al., 2017). The liposomes prepared in our study exhibited comparable characteristics to the 
ones described in the above-mentioned papers. In particular, the authors found that PEGylated 
formulations exhibited a reduced binding efficacy compared to plain and chitosan-coated 
ones, whereas chitosan-coated liposomes were binding mucin significantly more compared to 
plain ones (Jøraholmen et al., 2017). 
As previously stated, the interaction of liposomal formulations with the mucus layer can 
be affected by numerous factors, such as the pH of the physiological environment, pH of the 
specific formulation and pKa and related degree of ionization of the associated drug (Groo 
and Lagarce, 2014; Jøraholmen et al., 2017; Lieleg et al., 2010; Shaw et al., 2005). In this 
study, chitosan-coated formulations were prepared at acidic pH and were then adjusted to pH 
7.40. This process was carried out to ensure the same pH environment of the liposome-
associated drug for all formulations (plain, chitosan-coated, PEGylated liposomes). This pH 
was selected as a model pH, however the next step would be to adjust it to the targeted 





The permeability of metronidazole, indomethacin and naproxen from different 
liposome formulations (Fig.6) indicated decreased permeability for liposomally-associated 
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drugs compared to drugs in solution, confirming that liposomes assured a sustained release of 
the associated drugs. This is a very important feature considering prolonged release of drugs 
at the administration site, e.g. vaginal site (Jøraholmen et al., 2014). 
For metronidazole-containing liposomes, the drug permeability did not vary between 
the different formulations in the absence of mucus, suggesting that the chitosan coating and 
PEGylation processes had a negligible effect on drug release from the liposomes compared to 
the plain ones, evidence supported by the results obtained by Chen et al. (2013). However, in 
the presence of the mucus layer, metronidazole’s permeability changed according to the type 
of liposome formulation. In fact, chitosan-coated liposomes displayed a lower permeability of 
the drug compared to the plain ones, suggesting that the potential interaction between mucus 
and the chitosan-coating could slow down the permeation process of metronidazole, whereas 
PEGylated liposomes could easily penetrate through the mucus layer, contributing to a higher 
permeability. These results can be also explained by the different zeta potentials of the three 
formulations. Chitosan-coated liposomes, bearing a slightly positive zeta potential, could 
interact with the negatively charged mucus leading to a mucoadhesive effect, whereas the 
PEGylated liposomes, having a slightly negative zeta potential, could freely diffuse through 
the mucus layer. These results are supported by the findings of Chen and colleagues (2013), 
who clearly depicted the different mucus penetration potentials of plain phosphatidylcholine, 
chitosan-coated and Pluronic®-modified liposomes in ex vivo penetration studies. Their in 
vivo pharmacokinetic study further demonstrated that the Pluronic®-modified formulation 
(bearing a zeta potential of -4 mV) could provide the best oral absorption profile for the 
chosen drug, indicating that the ex vivo data correlate well with the in vivo one.  
The indomethacin- and naproxen-containing liposomes, exhibited a different 
penetration behaviour; indomethacin-containing plain, chitosan-coated and PEGylated 
liposomes were all found to be negatively charged (-25, -19 and -10 mV, respectively), a 
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feature that could lead to a lack of significant differences in the diffusion potential of the 
formulation and permeability of the drug. On the other hand, for the naproxen-containing 
liposomes, the PEGylation lead to an increase in permeability in the absence of mucus, 
suggesting an intrinsic penetration behaviour of the formulation. These deviations from the 
trends described above for the metronidazole-containing liposomes can be ascribed to the 
complexity of the physicochemical characteristics of the specific liposomal formulation, 
highlighting the problem/challenge of generalization when studying mucus diffusion 
properties and permeability potentials of different types of formulations (Fabiano et al., 2017; 
Netsomboon and Bernkop-Schnürch, 2016). Moreover, we found that the surface potential of 
the liposomes prepared varied according to the drug incorporated. Therefore, the 
mucopenetrating or mucoadhesive behaviour could mainly be linked to the specific zeta 
potential of the formulation. The permeability of the drugs depends on numerous factors 
including the penetration potential of the liposome formulation through the mucus layer and 
the interaction with it, the vesicle surface properties and size, but also the release of the drug 
from the delivery system, the chemical and structural properties of the specific compound and 
the drug equilibrium between the different layers. This confirms the high importance and need 
to have reliable in vitro permeability models able to predict the effect of mucus on the 






The novel mucus-PVPA model was developed and exploited to better mimic the in vivo 
environment of mucosal tissues by adding a mucus-simulating layer on top of the PVPA 
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barriers. The reliability of this upgraded version of the original PVPA model was proven in 
terms of the barrier tightness and functionality, and the barriers demonstrated maintained 
integrity under the chosen conditions. As expected, the mucus layer proved to be an additional 
barrier to the permeation of the selected drugs. The permeability varied depending on the 
different chemical structures and properties of the tested drugs. Moreover, the mucus-PVPA 
barriers were able to discriminate between different types of nanodelivery systems. The 
mucus-PVPA model was proven as a reliable tool in drug/active compound screening and can 
serve in the development and optimization of formulations destined for transmucosal delivery. 
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Figure and table captions 























Calcein CAL  1.8/9.2a -1.71b  - Fluorimeter Ex.: 485 
Em.: 520 
0.10-2.25 
Atenolol ATN  9.54c 0.16d -1.03 + UV 274 0.20-80.45 
Ibuprofen IBP  4.45c 3.97d 0.81 - UV 220 10-150 
Indomethacin IND  4.42c 4.27d 0.77 - HPLC-UV 254 0.016-320 
Metronidazole MTR  2.62e -0.02d 0.14 0 UV 320 30-200 
Naproxen NPR  4.18c 3.18d 1.70 - UV 270 0.8-84 
a: Flaten et al. 2006b 
b: Naderkhani et al. 2014b  
c: Avdeef 2003 
d: Benet et al. 2011 
e: Rediguieri et al. 2011 
 
 
Fig. 1: Papp values for calcein and electrical resistance of the PVPA barriers in the presence 
and absence (control) of different concentrations of mucin (10, 20, 40 mg/mL). The results are 




Fig. 2: Mucin viscosity of three mucin concentrations (10, 20 and 40 mg/mL). 
 
Fig. 3: Naproxen Papp (left axis) in the presence of a mucus layer with varying thicknesses 
(right axis, shaded area), and compared to the physiological mucus layer thickness (       ), 
dependent on the volume of mucus (mucin 10 mg/mL) added to the PVPA. The results are 
indicated as mean ± SD (n=3). Statistical significance (p < 0.05) was investigated with one-
way ANOVA using the Bonferroni post hoc test. 
* Statistically significant difference in  drugs’ Papp in the presence of different mucus volumes 




Fig. 4: Drug permeability in the presence and absence of different mucin concentrations (0, 
10, 20, 40 mg/mL). The results are indicated as mean ± SD (n=3). Statistical significance (p < 
0.05) was investigated with one-way ANOVA using the Bonferroni post hoc test. 
* Statistically significant difference in  drugs’ Papp in the presence of mucus with different 













Fig 5. Permeability of different compounds in the presence and absence of mucin (10 mg/mL) 
at room temperature (23-25°C) and at 37°C. The results are indicated as mean ± SD (n=3). 
Statistical significance (p < 0.05) was investigated with one-way ANOVA using the 
Bonferroni post hoc test. 















Table 2. Liposomal characteristics. The results are expressed as mean ± SD (n=3).  




Plain liposomes containing NPR 146.30 ± 13.15 (100%) 0.28 -2.32 ± 1.20 26.15 ± 2.19 
Coated liposomes containing NPR 138.10 ± 4.38 (95.2%) 0.38  0.19 ± 0.50 37.43 ± 5.79 
PEGylated liposomes containing NPR 128.00 ± 6.36 (99.8%) 0.18 -10.89 ± 2.13 23.58 ± 0.31 
Plain liposomes containing IND 140.85 ± 5.87 (97.6%) 0.27 -24.75 ± 0.35 83.30 ± 3.88 
Coated liposomes containing IND 134.15 ± 18.74 (96.5%) 0.30 -18.68 ± 1.53 73.87 ± 4.03 
PEGylated liposomes containing IND 96.22 ± 5.11 (98.3%) 0.23 -10.60 ± 0.34 77.81** 
Plain liposomes containing MTR 202.52 ± 2.24 (70.1%) 0.52 -2.13 ± 1.34 2.82 ± 0.14 
Coated liposomes containing MTR 162.27 ± 8.44 (68.9%) 0.63 1.91 ± 0.24 2.78 ± 0.01 
PEGylated liposomes containing MTR 105.40 ± 5.11 (98.6%) 0.20 -4.38 ± 0.519 2.58 ± 0.20 
* Naproxen (NPR), indomethacin (IND) and metronidazole (MTR) 
** Only one batch was prepared 
 
Fig. 6: Permeability of metronidazole, indomethacin and naproxen from different liposomal 
formulations in the presence and absence of mucin (10 mg/mL). The results are indicated as 
mean ± SD (n=3). Statistical significance (p < 0.05) was investigated with one-way ANOVA 
using the Bonferroni post hoc test. 
* Statistically significant difference in  drugs’ Papp between the highlighted bar and all the 




Fig. S1. Confocal laser scanning microscopy of the PVPA barrier labelled with rhodamine 
(red) after soaking for 3 hours in calcein solution (green). The two micrographs were taken 
from two different positions in the barrier. The white lines mark the placement of the cross-




Fig. S2. Confocal laser scanning microscopy of the PVPA barrier labelled with rhodamine 
(red) after soaking for 3 hours in mucin 10 mg/mL marked with calcein (green). The two 
micrographs were taken from two different positions in the barrier. The white lines mark the 




Fig. S3. Confocal laser scanning microscopy of the PVPA barrier labelled with rhodamine 
(red) after soaking for 3 hours in mucin 40 mg/mL marked with calcein (green). The two 
micrographs were taken from two different positions in the barrier. The white lines mark the 


















Confocal laser scanning microscopy 
Methods 
Confocal laser scanning microscopy (CLSM) was used to assess possible interactions between 
the mucin suspensions and the PVPA barriers. The barriers were prepared as described in 
section 2.2 with the only exception that 0.2 mol% of the Lipoid E80 was replaced by 1,2-
dioleoyl-sn-glycero-3-phophoethanolamine-N-(Lissamine rhodamine B sulfonyl) (ammonium 
salt) rhodamine (purchased from Avanti Polar Lipids, Inc., Alabama, USA) to visualise the 
lipids composing the barriers. Calcein solution (1.65 mg/mL) was used to produce two 
suspensions with different mucin concentrations (10 mg/mL and 40 mg/mL). Before the 
experiment, 50 µL of either calcein solution or mucin suspensions (10 mg/mL and 40 mg/mL) 
were added to the donor compartment and the system was left to soak for three hours in the 
acceptor wells containing 600 µL of PBS pH 7.4 to visualise possible aqueous channels 
throughout the barriers’ thickness caused by the mucus layer . After soaking, the donor fluids 
were removed and the filters carefully detached from the inserts. The CLSM analysis was 
performed on a Leica TCS SP5 microscope (Leica Microsystems CMS GmbH, Mannheim, 
Germany) equipped with an Argon laser for calcein and a DPSS 561 laser for rhodamine. Laser 
lines of 488 and 568 nm were used to excite calcein and rhodamine, respectively. For calcein, 
fluorescence was detected in the spectral range of 500-550 nm, while rhodamine was detected 
at 570-610 nm (Ternullo et al., 2017). Images were acquired with a 10x0.4 objective taking z-
section micrographs (z-step size of 0.25 µm). To make sure the defects were not present 
throughout the whole thickness of the barriers, 420 z-sections were analysed for each barrier. 
The gain, off-set and zoom were kept as constant as possible to maintain the same setup for all 
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the micrographs. The micrographs were superimposed using Volocity® v.6.3 software 
(PerkinElmer, MA, USA). 
 
Results 
In a previous study, Flaten and colleagues have analysed via confocal electron scanning 
microscopy the filters composing the PVPA barriers without the addition of the liposomes 
(Flaten et al., 2006a) and used it as a control in order to visualise how aqueous channels look 
like in the absence of the lipid component. By comparing this control to confocal images of 
the PVPA barriers, they were able to see that no significant aqueous channels were present 
throughout the thickness of the PVPA barriers. In our study, we wanted to visualise if the 
addition of mucus would cause the formation of aqueous channels in the PVPA barriers, 
especially since the high permeability of molecules (in or case the highly hydrophilic marker 
calcein) can be traced back to a significant number or defects and aqueous channels in the 
barriers (Richter et al., 2016). 
Confocal images are shown in Fig. S1 (calcein solution in the donor), Fig. S2 (10 mg/mL mucin 
suspended in calcein solution the donor) and Fig. S3 (40 mg/mL mucin suspended in calcein 




Fig. S1 displays the PVPA barrier after exposure to the calcein solution, showing a dominant 
red fluorescence representing the rhodamine-associated PVPA barrier and a green 
fluorescence of the hydrophilic calcein solution. The cross-sections a and b taken in different 
positions confirm lack of aqueous channels through the barrier, suggesting the maintenance of 
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the barrier’s integrity in the given condition. This is in agreement with previous CLSM 




Fig. S2 indicates that no aqueous channels were present after the exposure to the lowest 




As it can be observed from Fig. S3, calcein was more abundant as compared to previous 
results (Fig. S1 and S2). The first cross-section (a) indicates a barrier similar to the one when 
PVPA barrier was exposed to calcein solution (Fig. S1 and S2). In the second micrograph and 
cross-section (b) calcein was visible in a higher concentration in the donor side of the barrier. 
However, no significant breaches in the barrier were observed, suggesting that the barrier’s 
integrity was maintained also in the presence of the highest concentration of mucus 
suspension. 
 
